Novel Biological and Molecular Characterization in Radiopharmaceutical Preclinical Design.
digital autoradiography system
nuclear imaging
pre-clinical model
radiopharmaceutical
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Oct 2021
21 Oct 2021
Historique:
received:
21
09
2021
revised:
13
10
2021
accepted:
19
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
In this study, the potential of a digital autoradiography system equipped with a super resolution screen has been evaluated to investigate the biodistribution of a 18F-PSMA inhibitor in a prostate cancer mouse model. Twelve double xenograft NOD/SCID mice (LNCAP and PC3 tumours) were divided into three groups according to post-injection time points of an 18F-PSMA inhibitor. Groups of 4 mice were used to evaluate the biodistribution of the radiopharmaceutical after 30-, 60- and 120-min post-injection. Data here reported demonstrated that the digital autoradiography system is suitable to analyse the biodistribution of an 18F-PSMA inhibitor in both whole small-animal bodies and in single organs. The exposure of both whole mouse bodies and organs on the super resolution screen surface allowed the radioactivity of the PSMA inhibitor distributed in the tissues to be detected and quantified. Data obtained by using a digital autoradiography system were in line with the values detected by the activity calibrator. In addition, the image obtained from the super resolution screen allowed a perfect overlap with the tumour images achieved under the optical microscope. In conclusion, biodistribution studies performed by the autoradiography system allow the microscopical modifications induced by therapeutic radiopharmaceuticals to be studied by comparing the molecular imaging and histopathological data at the sub-cellular level.
Identifiants
pubmed: 34768368
pii: jcm10214850
doi: 10.3390/jcm10214850
pmc: PMC8584913
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : PUGLIA FESR 2014-2020
ID : PUGLIA FESR 2014-2020
Références
Ann Ist Super Sanita. 2017 Jul-Sep;53(3):185-191
pubmed: 28956796
Genes Dev. 2003 Mar 1;17(5):545-80
pubmed: 12629038
Insights Imaging. 2015 Apr;6(2):141-55
pubmed: 25763994
J Nucl Med. 2016 Feb;57 Suppl 1:60S-8S
pubmed: 26834104
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1222-1225
pubmed: 30859431
Q J Nucl Med Mol Imaging. 2009 Aug;53(4):365-73
pubmed: 19834445
Vet Radiol Ultrasound. 2005 Mar-Apr;46(2):162-70
pubmed: 15869162
Clin Med (Lond). 2017 Oct;17(5):458-461
pubmed: 28974599
Int J Mol Sci. 2017 Apr 12;18(4):
pubmed: 28417933
Future Oncol. 2018 May;14(11):1013-1015
pubmed: 29623724
Nucl Med Biol. 2019 Jan - Feb;68-69:66-79
pubmed: 30770226
Nat Rev Cancer. 2014 Jul;14(7):481-93
pubmed: 24943811
Cell Mol Biol (Noisy-le-grand). 1995 Feb;41(1):57-64
pubmed: 7773137
J Nucl Med. 1990 Dec;31(12):2058-63
pubmed: 2266409
Adv Cancer Res. 2014;124:235-56
pubmed: 25287691
Am J Nucl Med Mol Imaging. 2016 Nov 30;6(6):310-327
pubmed: 28078184
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):646-649
pubmed: 29893276
J Nucl Med Technol. 2012 Sep;40(3):157-65
pubmed: 22582006
Recent Results Cancer Res. 2013;187:257-310
pubmed: 23179885
Per Med. 2018 Nov;15(6):457-459
pubmed: 30398094
Nat Rev Urol. 2018 Apr;15(4):205
pubmed: 29508849
F1000Res. 2018 Aug 24;7:
pubmed: 30467517
J Clin Med. 2019 Oct 11;8(10):
pubmed: 31614564
Contrast Media Mol Imaging. 2019 Jul 1;2019:9429761
pubmed: 31354394
Urol Oncol. 2019 May;37(5):297.e19-297.e31
pubmed: 30827759
J Nucl Med. 2016 Feb;57(2):171-2
pubmed: 26405165
IEEE Trans Med Imaging. 2015 Mar;34(3):707-15
pubmed: 24759983
Electrophoresis. 1990 May;11(5):355-60
pubmed: 2194789
Int J Mol Sci. 2019 Nov 11;20(22):
pubmed: 31718020
Oncotarget. 2016 Nov 29;7(48):79428-79441
pubmed: 27765906
Theranostics. 2018 Nov 29;8(22):6210-6232
pubmed: 30613293
Nucl Med Commun. 2014 Dec;35(12):1193-6
pubmed: 25211627
Phys Med Biol. 2019 Feb 18;64(4):045015
pubmed: 30650398